Haywood analyst Neal Gilmer has reiterated their bullish stance on CRLBF stock, giving a Buy rating on February 25.
Neal Gilmer has given his Buy rating due to a combination of factors including Cresco Labs’ ability to generate cash effectively and maintain a strong cash position. The company’s financial results for Q4 2024 showed a slight revenue increase above expectations, although margins were slightly lower than anticipated. Despite this, Cresco Labs demonstrated improved cash flow generation compared to previous years, with a focus on enhancing the quality of revenue.
Furthermore, Cresco Labs’ vertically integrated operations in key markets like Ohio, Pennsylvania, and Florida are poised to drive future growth. The company is also expanding into new markets such as Kentucky, which is expected to contribute to its growth trajectory in 2025 and beyond. These strategic initiatives, coupled with a solid cash balance, underpin Neal Gilmer’s confidence in Cresco Labs’ potential, justifying the Buy rating.
In another report released on February 25, Canaccord Genuity also maintained a Buy rating on the stock with a C$3.25 price target.
Questions or Comments about the article? Write to editor@tipranks.com